Orserdu, a drug from Menarini Group subsidiary Stemline Therapeutics, is now approved for treating breast cancers that carry the ESR1 mutation. The drug is the first approved oral therapy from a class of therapies called selective estrogen receptor degraders (SERDs).
The final rule calls for stricter audits on Medicare Advantage plans. AHIP president and CEO Matt Eyles referred to the rule as "unlawful and fatally flawed."
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
Paradigm, a new startup co-incubated by ARCH Venture Partners and General Catalyst, recently launched with $203 million in Series A funding. The company is focused on improving equitable access to trials by creating a less fragmented and more efficient clinical research ecosystem.
Season one focusing on chronic disease management kicks off with a conversation with Stephanie Tilenius, CEO of Vida Health that aims to treat both the mind and the body.
Point solutions for areas like behavioral health, family planning and more have risen in popularity in recent years, experts said. But as employers deal with point solution fatigue, healthcare navigation companies are proving beneficial.
Less than 20% of behavioral healthcare providers collect data on how patients are progressing with their treatment. To buck this trend, Two Chairs is rolling out “mental health snapshots,” which are consistent summaries of patients’ well-being designed to offer real-time insight to both clinicians and clients.
Vector BioMed has developed a technology platform for designing and manufacturing the lentiviruses used to deliver cell and gene therapies. The startup is launching as the field continues to experience shortages of these viral vectors.
Ciox recently partnered with Virginia-based non-profit health system Sentara Healthcare to pilot a tool that makes it easier for expectant mothers to access their health records. The fact that patients’ pregnancy data get trapped in silos is problematic because providers can use that information to predict complications and intervene sooner.
Blue Shield of California's new health plan, Virtual Blue, gives members virtual access to primary care through Accolade and virtual access to specialty care through TeleMed2U. If needed, they can also receive in-person care through the payer's PPO network.
Smile Digital Health recently raised $30 million in Series B capital. The startup sells its health data fabric platform to providers, payers, digital health vendors and researchers. The platform gives customers the ability to store, search and evaluate patient information.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
The Kaiser Family Foundation examined pre-pandemic data to determine what will happen to those disenrolled from Medicaid and CHIP once the continuous enrollment requirement ends March 31. The analysis found that 65% of those disenrolled went through a period of uninsurance.
Last year’s digital health investment trends have left some startups feeling uneasy about their ability to raise capital in the new funding environment. Venture capitalists think companies that have a demonstrable return on investment and serve multiple stakeholders will probably have the easiest time securing capital, while point solutions and startups in crowded markets will face a tougher environment.
A recent NEJM publication concluded that although colonoscopy is widely used as a dependable screening test to detect colorectal cancer, its overall effect on the risks of colorectal cancer death is potentially less clear than previously reported. The doubt sprouting from this study is misplaced, dangerous and will potentially lead to more deaths from this disease.
Now that numerous calls for repeal and legal challenges brought against the ACA over the years have failed, health plans can finally invest confidently in this line of business.
Was Livongo a good business? As Burke, now CEO of Quantum Health, touts its strength to investors ahead of a potential IPO, should the Livongo-Teladoc history give them pause?
